Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $35.71.
DAWN has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, July 30th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. JPMorgan Chase & Co. cut their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Finally, Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the stock from $11.00 to $24.00 in a report on Thursday, August 1st.
Check Out Our Latest Report on DAWN
Insider Activity
Institutional Trading of Day One Biopharmaceuticals
Several large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in Day One Biopharmaceuticals by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 452,934 shares of the company’s stock valued at $6,613,000 after buying an additional 5,796 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at $156,000. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at $29,000. Franklin Resources Inc. increased its position in Day One Biopharmaceuticals by 4.2% during the 4th quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock worth $61,857,000 after purchasing an additional 169,463 shares in the last quarter. Finally, NEOS Investment Management LLC purchased a new stake in Day One Biopharmaceuticals during the 4th quarter worth about $226,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.
Day One Biopharmaceuticals Price Performance
Shares of NASDAQ:DAWN opened at $14.78 on Friday. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $18.07. The stock has a market cap of $1.29 billion, a P/E ratio of -5.89 and a beta of -1.51. The firm has a fifty day moving average price of $14.27 and a 200 day moving average price of $14.55.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million. Sell-side analysts expect that Day One Biopharmaceuticals will post -1.68 EPS for the current fiscal year.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
- Five stocks we like better than Day One Biopharmaceuticals
- Investing In Automotive Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Airline Stocks – Top Airline Stocks to Buy Now
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Why is the Ex-Dividend Date Significant to Investors?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.